Generic Jatenzo Availability
Last updated on May 7, 2025.
Jatenzo is a brand name of testosterone, approved by the FDA in the following formulation(s):
JATENZO (testosterone undecanoate - capsule;oral)
-
Manufacturer: TOLMAR
Approval date: March 27, 2019
Strength(s): 158MG [RLD], 198MG [RLD], 237MG [RLD]
Is there a generic version of Jatenzo available?
No. There is currently no therapeutically equivalent version of Jatenzo available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Jatenzo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Patent 10,543,219
Issued: January 28, 2020
Inventor(s): Dudley Robert E. & Constantinides Panayiotis P.
Assignee(s): Clarus Therapeutics, Inc.A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.
Patent expiration dates:
- April 12, 2030✓
- April 12, 2030
-
Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Patent 10,617,696
Issued: April 14, 2020
Inventor(s): Dudley Robert E. & Constantinides Panayiotis P.
Assignee(s): Clarus Therapeutics, Inc.A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.
Patent expiration dates:
- April 12, 2030✓✓
- April 12, 2030
-
Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
Patent 11,179,402
Issued: November 23, 2021
Inventor(s): Dudley Robert E. & Constantinides Panayiotis P.
Assignee(s): Clarus Therapeutics, Inc.A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.
Patent expiration dates:
- April 14, 2026✓✓
- April 14, 2026
-
Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Patent 11,179,403
Issued: November 23, 2021
Inventor(s): Dudley Robert E. & Constantinides Panayiotis P.
Assignee(s): Clarus Therapeutics, Inc.A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.
Patent expiration dates:
- April 12, 2030✓
- April 12, 2030
-
Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
Patent 11,331,325
Issued: May 17, 2022
Inventor(s): Dudley; Robert E. et al.
Assignee(s): Clarus Therapeutics, Inc. (Northbrook, IL)A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.
Patent expiration dates:
- January 6, 2027✓
- January 6, 2027
-
Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Patent 11,426,416
Issued: August 30, 2022
Inventor(s): Dudley Robert E. & Constantinides Panayiotis P.
Assignee(s): Clarus Therapeutics, Inc.A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.
Patent expiration dates:
- April 12, 2030✓
- April 12, 2030
-
Methods of treating testosterone deficiency
Patent 11,564,933
Issued: January 31, 2023
Inventor(s): Dudley; Robert E. et al.
Assignee(s): Tolmar, Inc. (Fort Collins, CO)Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone esters are provided. In some embodiments, the subject has adequately controlled blood pressure.
Patent expiration dates:
- April 12, 2039✓
- April 12, 2039
-
Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
Patent 8,241,664
Issued: August 14, 2012
Inventor(s): Dudley Robert E. & Constantinides Panayiotis P.
Assignee(s): Clarus Therapeutics, IncA drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.
Patent expiration dates:
- March 29, 2029✓✓
- March 29, 2029
-
Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Patent 8,492,369
Issued: July 23, 2013
Inventor(s): Dudley Robert E. & Constantinides Panayiotis P.
Assignee(s): Clarus Therapeutics IncA pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.
Patent expiration dates:
- December 20, 2030✓✓
- December 20, 2030
-
Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Patent 8,778,916
Issued: July 15, 2014
Inventor(s): Dudley Robert E. & Constantinides Panayiotis P.
Assignee(s): Clarus Therapeutics, Inc.A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.
Patent expiration dates:
- April 12, 2030✓
- April 12, 2030
More about Jatenzo (testosterone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Latest FDA alerts (7)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: androgens and anabolic steroids
- Breastfeeding
- En español
Patient resources
Other brands
AndroGel, Xyosted, Depo-Testosterone, Androderm, ... +13 more
Professional resources
Other brands
AndroGel, Xyosted, Depo-Testosterone, Androderm, ... +12 more
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
